BAD and neoplasm: We found that sst5TMD4 could exert its function through the activation of multiple critical mediators of various cancer-relevant signaling pathways closely associated with malignancy progression in different tumor pathologies [8,44,45,46,47,48,49], such as an activation of AKT (i.e., AKT1, BAD, EIF4EBP1, P70S6K, PDK1, GSK3A, CDKN1B, and PRASA40), JAK/STAT (i.e., SRC, STAT1, STAT2, and STAT3), NF-κB (i.e., ATM, EIF2A, HDAC2, TAK1, TBK1, and ZAP70), and TGF-β (i.e., FOS, JUN, ATF2, FOS, JUN, SMAD1, SMAD4, and SMAD5) pathways.